Pharming Group NV (PHARM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.121x

Based on the latest financial reports, Pharming Group NV (PHARM) has a cash flow conversion efficiency ratio of 0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€32.03 Million ≈ $37.44 Million USD) by net assets (€264.64 Million ≈ $309.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pharming Group NV balance sheet independence to measure how much of total assets are equity-financed.

Pharming Group NV - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pharming Group NV cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Pharming Group NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Surge Energy Inc. TO:SGY	0.086x
Afya Ltd NASDAQ:AFYA	0.091x
GH RESEARCH PLC DL-025 F:1KA	N/A
Argo Properties NV TA:ARGO	0.019x
Magic Software Enterprises Ltd TA:MGIC	0.064x
Shenzhen Liande Automatic Equipment Co Ltd SHE:300545	-0.012x
China Shineway Pharmaceutical Group Limited F:C1S	0.020x
Suzhou Etron Technologies Co Ltd SHG:603380	0.091x

Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)

The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Pharming Group NV stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€214.16 Million ≈ $250.38 Million	€-1.79 Million ≈ $-2.10 Million	-0.008x	+91.51%
2023-12-31	€198.05 Million ≈ $231.55 Million	€-19.55 Million ≈ $-22.85 Million	-0.099x	-188.20%
2022-12-31	€204.64 Million ≈ $239.24 Million	€22.90 Million ≈ $26.77 Million	0.112x	-40.31%
2021-12-31	€192.72 Million ≈ $225.31 Million	€36.13 Million ≈ $42.23 Million	0.187x	-62.14%
2020-12-31	€183.73 Million ≈ $214.80 Million	€90.98 Million ≈ $106.36 Million	0.495x	-22.12%
2019-12-31	€117.26 Million ≈ $137.09 Million	€74.56 Million ≈ $87.16 Million	0.636x	-2.76%
2018-12-31	€70.64 Million ≈ $82.58 Million	€46.19 Million ≈ $54.00 Million	0.654x	-67.83%
2017-12-31	€22.56 Million ≈ $26.37 Million	€45.84 Million ≈ $53.60 Million	2.032x	+658.01%
2016-12-31	€28.89 Million ≈ $33.77 Million	€-10.52 Million ≈ $-12.30 Million	-0.364x	+47.13%
2015-12-31	€26.06 Million ≈ $30.47 Million	€-17.95 Million ≈ $-20.99 Million	-0.689x	-289.43%
2014-12-31	€36.29 Million ≈ $42.43 Million	€-6.42 Million ≈ $-7.50 Million	-0.177x	+89.31%
2013-12-31	€6.92 Million ≈ $8.09 Million	€-11.45 Million ≈ $-13.39 Million	-1.655x	-223.33%
2012-12-31	€-10.12 Million ≈ $-11.83 Million	€-13.58 Million ≈ $-15.88 Million	1.342x	-89.84%
2011-12-31	€-1.54 Million ≈ $-1.80 Million	€-20.34 Million ≈ $-23.78 Million	13.210x	+2676.91%
2010-12-31	€13.43 Million ≈ $15.70 Million	€-6.89 Million ≈ $-8.05 Million	-0.513x	+64.11%
2009-12-31	€19.07 Million ≈ $22.30 Million	€-27.24 Million ≈ $-31.85 Million	-1.428x	-75.31%
2008-12-31	€17.45 Million ≈ $20.40 Million	€-14.21 Million ≈ $-16.62 Million	-0.815x	-30.04%
2007-12-31	€50.58 Million ≈ $59.13 Million	€-31.69 Million ≈ $-37.05 Million	-0.626x	-59.15%
2006-12-31	€65.78 Million ≈ $76.91 Million	€-25.89 Million ≈ $-30.27 Million	-0.394x	+12.20%
2005-12-31	€34.04 Million ≈ $39.79 Million	€-15.26 Million ≈ $-17.84 Million	-0.448x	--

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$736.80 Million

€630.22 Million EUR

Market Cap Rank

#10212 Global

#57 in Netherlands

Share Price

€0.90

Change (1 day)

+2.47%

52-Week Range

€0.88 - €1.78

All Time High

€1.78